Red light emitting diode as an adjuvant treatment for epidermal growth factor receptor inhibitors-induced paronychia. (19th May 2022)

• Record Type: Journal Article
• Authors: Jornsamer, Chanoknan; Theerawattanawit, Chinathip; Wichayachakorn, Chanitwan; Panchaprateep, Ratchathorn; Kerr, Stephen J.; Asawanonda, Pravit; Rerknimitr, Pawinee
• Is Part Of: Journal of dermatological treatment. Volume 33:Number 4(2022)
• Page Start: 1990
• Page End: 1994
• Publication Date: 2022-05-19
• Subjects: Epidermal growth factor receptor inhibitors -- EGFRi -- red light -- LED -- paronychia -- treatment; Skin -- Diseases -- Treatment -- Periodicals; Skin Diseases -- drug therapy -- Periodicals; Skin Diseases -- therapy -- Periodicals; 616.5
• DOI: 10.1080/09546634.2021.1927950
• Languages: English
• ISSNs: 0954-6634

Abstract

Abstract: We evaluated the efficacy and safety of red light LED as an adjuvant treatment for epidermal growth factor receptor inhibitor-induced paronychia. Eight patients were recruited in this randomized, single-blinded controlled trial. They were randomized to receive red-light on one hand or foot 2–3 times/week for 6 weeks while the contralateral side served as controls. The standard treatments were continued. Erythema and lesion elevation observed by Anthera ® 3D, severity and pain scores were obtained at weeks 0, 2, 4, 6, and 8. The red light group showed significantly lower erythema, severity, and pain scores at weeks 4, 6, and 8. The elevation was significantly lower in the red light group at every follow-up visit. No adverse events occurred. Red light therapy may be an option as adjunctive treatment for EGFRi-induced paronychia.